Here are the Form 4 insider transactions from Niki BioSolutions, Inc. (NIKI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NIKI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIKI filings page.
Laura A. Philips, a director of Niki BioSolutions, Inc. (NIKI), acquired 8,000 stock options in a grant on July 22, 2026, with an exercise price of $8.83 per share and an expiration date of July 22, 2036. The grant left her with 8,000 options held directly. Under the stated schedule, 2,000 options vested immediately upon the closing of the merger; the remaining 6,000 vest in three equal quarterly installments of 2,000, starting on the first business day of the first full quarter following the effective date of the merger.
At Niki BioSolutions, Inc. (NIKI), director and 10% owner Kira Sheinerman acquired 8,000 stock options on July 22, 2026. Of those options, 2,000 vested immediately upon the closing of the merger; the remaining 6,000 vest in three equal quarterly installments of 2,000, commencing on the first business day of the first full quarter following the merger’s effective date.
Niki BioSolutions, Inc. director and 10% owner Kira Sheinerman received an award of 8,000 stock options on July 22, 2026, exercisable at $8.83 per share and expiring July 22, 2036. The options cover 8,000 common shares. Under the award terms, 2,000 options vested immediately upon the merger closing; the remaining 6,000 vest in three equal quarterly installments of 2,000, beginning on the first business day of the first full quarter following the merger’s effective date.